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Autoimmune diseases (ADs) are estimated to affect between 5 and 8 % of the US population, and approximately
80 % of these patients are women. Sjögren’s syndrome (SS) is an AD that occurs predominately in women over
men (16:1). The hallmark characteristic of SS is diminished secretory production from the primary exocrine gland
and the lacrimal or salivary glands resulting in symptoms of dry eye and mouth. The disease is believed to be
mediated by an inflammatory and autoantibody response directed against salivary and lacrimal gland tissues. This
review will examine the literature on sex differences in the immune response of patients and animal models of
Sjögren’s syndrome in order to gain a better understanding of disease pathogenesis.
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Introduction
Autoimmune diseases (ADs) are estimated to affect be-
tween 5 and 8 % of the US population or 14.7 to 23.5 mil-
lion people [1, 2]. Strikingly, around 80 % of those affected
are women [1]. ADs with a recognized sex difference in
incidence in women compared to men include multiple
sclerosis (2:1), autoimmune hepatitis (4:1), Graves’ disease
(7:1), and Hashimoto’s thyroiditis (19:1) [3, 4]. A female to
male predominance also occurs for the rheumatic auto-
immune diseases, dermatomyositis (2:1), rheumatoid arth-
ritis (RA) (3:1), systemic lupus erythematosus (SLE) (7:1),
systemic sclerosis (12:1), and Sjögren’s syndrome (SS)
(16:1) [4–7]. ADs that occur more frequently in men
compared to women include type 1 diabetes (1.2:1),
idiopathic pulmonary fibrosis (11:7), and myocarditis (2:1)
[4, 8]. Distinct immunopathologic differences between
male and female predominant ADs suggest that sex hor-
mone regulation of inflammation may provide clues to the
pathogenesis of disease. Because inflammation and auto-
antibody responses are directly influenced by sex hormones,
sex hormones most likely influence immune-mediated* Correspondence: Fairweather.DeLisa@mayo.edu
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chemicals in the context of genetic predisposition.
This review will explore the literature on sex differ-
ences in the immune response of patient and animal
models of SS in order to gain a better understanding
of disease pathogenesis, with a focus on studies and
review articles that have been published for SS.
Sjögren’s syndrome has an estimated prevalence of
0.5–4.8 %, affecting approximately 1.5 to 4 million
people in the USA based on a total population of 300
million [9, 10], making it by some estimates the second
most common autoimmune disease affecting women
after Hashimoto’s thyroiditis [4, 11]. Because no prevalence
studies have been performed in the USA, population-based
incidence data from Olmsted County, Minnesota and
prevalence data from several international studies have
been used to infer SS prevalence in the US [12]. This study
found a prevalence ranging from 0.2 to 1.4 %, placing SS
second to RA among rheumatic diseases [12].
The hallmark characteristic of SS is diminished secretory
production from the primary exocrine glands, the lacrimal
(involved in tear production) and/or the salivary glands. As
a result, dry eye (keratoconjunctivitis sicca) and/or dry
mouth (xerostomia) are among the most commonly re-
ported symptoms of SS. Aside from the exocrine tar-
gets, SS also affects the lungs, kidneys, thyroid, muscle,
and skin and manifests with symptoms of fatigue, pain,
depression, cutaneous lesions, and mild arthritis. Becauseis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 2 Factors suggesting autoantibodies and ICs involved in
the pathogenesis of Sjögren’s syndrome (SS)
• Female preponderance (i.e., estrogen’s central role in
increasing autoantibodies)
• Women respond to infection, vaccination, and trauma
with more antibodies compared to men
• Autoantibodies (i.e., Ro/SSA and La/SSB) part of SS classification criteria
• B/plasma cells in salivary glands of SS patients release
Ro/SSA and La/SSB, which are ANA-type autoantibodies
• B cell hyperactivity (i.e., hypergammaglobulinemia) found
in SS patients
• Pregnancy increases the risk for SS in young women; estrogen
with prolactin increases Ro/SSA and La/SSB autoantibodies
• Some studies report more autoantibodies in women with SS
compared to men
• Rheumatoid factor (RF), which forms ICs, present in 60–80 %
of SS patients
• RF predicts severity of SS
• Elevated IgA in SS patients binds RF to form ICs and damage
salivary glands
• Genetic predisposition in SS patients: low copy number of the
IgG receptor FcγRIIIb gene FCGR3B reduces clearance of ICs
• B cells are activated by TLRs and BAFF on their surface; TLRs
and BAFF correlate with autoantibody levels in SS patients
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nonspecific, it has been estimated that symptoms can
be present for 6 to 7 years before a diagnosis is made,
dramatically reducing quality of life [13]. Historically, if
the diagnosis is made in the absence of another AD, it has
been classified as primary Sjögren’s syndrome (pSS), but
SS is commonly associated with other ADs like rheuma-
toid arthritis, Raynaud’s phenomenon, and thyroiditis [14].
When patients present with a potentially associated dis-
ease (like another well-defined connective tissue dis-
ease), the disease has been termed secondary Sjögren’s
syndrome (sSS) [15, 16]. More recently, the American
College of Rheumatology provided a new classification
criterion for SS suggesting that SS that occurs as a single
entity should be called “isolated SS” and SS associated
with other ADs be termed “associated SS” [17]. Addition-
ally, they recommended that all those who fulfill the classi-
fication criteria should be diagnosed with SS regardless of
whether they have another AD [17].
Autoimmune diseases are chronic inflammatory condi-
tions where memory-specific T and B cells and antibodies
are directed against self-antigens. Autoimmunity occurs
frequently in undiseased individuals, but pathology or overt
autoimmune disease generally develops when multiple or
high titer autoantibodies are directed against a target tissue
[8]. For this reason, a component of the classification cri-
teria for most autoimmune diseases is based on the pres-
ence of particular autoantibodies in the sera. Pathogenic
immune complexes (ICs) form when autoantibodies bind
self-antigen and activate the complement cascade. Depo-
sition of ICs often damages host tissues by causing direct
cytotoxicity to host cells and recruiting inflammation to
the damaged site [7, 18].
In addition to dry eyes and mouth, for a positive SS classi-
fication, patients may present with exocrine gland lympho-
cyte infiltration and/or autoantibodies against Ro (also called
Sjögren’s syndrome-associated antigen-A/SSA) and/or
La (SSB) (Table 1) [15, 17]. Ro and La were named from
the first two letters of the surname of the donors who pro-
vided the reactive serum and are cytoplasmic and nuclear
ribonucleoproteins (i.e., anti-nuclear antibodies (ANA))
found in all cells [19]. An overriding question remains as
to why autoantibodies and ICs target the lacrimal and sal-
ivary glands when these antigens are present in every cell.Table 1 Revised European-American classification criteria for
Sjögren’s syndrome (SS) modified from [15, 17]. Note that not
all criteria are required for classification of SS
• Salivary gland inflammation confirmed by histology
• Autoantibodies against Ro/SSA and/or La/SSB
• Ocular signs and symptoms of dry eye
• Oral signs and symptoms of dry mouth including reduced salivary flow
(≤1.5 mL in 15 min)Rheumatoid factor (RF), which are autoantibodies directed
against the Fc portion of IgM, IgG, or IgA antibodies, are
often found in autoimmune rheumatic diseases like SS,
RA, and SLE. RF autoantibodies occur in 60–80 % of SS
patients [20, 21] and have been found to predict the sever-
ity of disease in patients indicating that RF may contribute
to the pathogenesis of disease and suggesting an impor-
tant role for IC deposition in this process (Table 2) [20].
RF bound to other autoantibodies promotes IC formation
and increases the potential for deposition. RF functions in-
clude enhancing normal immune responses, particularly
against infections; promoting complement fixation, anti-
gen presentation, and the avidity of IgG; and improving
clearance of ICs by macrophages [20, 21]. These roles help
clear infections but can also drive autoimmune disease.
Plasma B cells within the salivary glands of SS patients
have been found to produce Ro/SSA and La/SSB autoan-
tibodies [22]. The inflammatory infiltrate in SS patients
includes T and B cells, dendritic cells (DCs), and macro-
phages, while immune-mediated damage is believed to be• IC deposition in salivary glands activates TLRs on epithelial cells
generating the “IFN signature” that is associated with SS pathology
• Viral infections suspected in “triggering” SS activate TLRs to produce
“IFN signature” as well as strongly inducing IC formation
• ICs known to produce tissue pathology by increasing inflammation,
fibrosis, and apoptosis—endpoint characteristic of SS
• SS in women is associated with other ADs that occur predominantly
in women like RA, thyroiditis, and Raynaud’s phenomenon—diseases
where autoantibodies and ICs are believed to promote disease
pathology
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rosis [19].
Immunopathogenesis of SS
A number of recent reviews describe the current under-
standing of the pathogenesis of SS [11, 23–25]. However,
they do not specifically address the role of sex differences
in disease pathogenesis, which is the purpose of this review.
In general, recent reviews emphasize the importance of B
cell activation and an “interferon signature” in the path-
ogenesis of disease, which has resulted in SS being called
“lupus of the mucosa” by some [11]. Genetic polymor-
phisms in genes associated with activation of type I (α and
β) and type II (γ) interferons (IFNs) (like IRF5 and STAT4)
have been found to be associated with the development of
SS [11, 25–27]. By microarray, 19 SS patients (all post-
menopausal women) had an elevated IFN signature in per-
ipheral blood compared to 10 healthy controls (5 men and
5 premenopausal women) [28]. The innate immune re-
sponse appears to play a major role in the disease process.
Toll-like receptors (TLRs) that are associated with viral in-
fections and that upregulate NFκB and IFNs, like TLR3,
TLR4, TLR7, and TLR9, are elevated in SS patients [25, 29].
Salivary gland epithelial cells from SS patients express not
only TLR4 but also costimulatory molecules like CD86 in-
dicating that they may play a role in activating the innate
immune response [11, 29]. This may be especially impor-
tant after damage to the salivary gland since TLR4 is acti-
vated not only by infections but also by damaged self-tissue
(DAMPs).
B cell hyperactivity is another hallmark of SS. Not only
does activation of B cells result in hypergammaglobuline-
mia and autoantibodies against Ro/SSA and La/SSB but
also B cell activation via TLRs and B cell activating factor
(BAFF) on their surface increases IFNs [11, 24]. BAFF is
further elevated by IFNs in a positive feedback loop. Ele-
vated BAFF levels in SS patients were found to correlate
with their autoantibody levels [30]. Elevated IgA that binds
RF to form ICs is a common finding during SS and these
IgA-RF ICs are strongly associated with an abnormal SG
biopsy in patients [24, 31, 32]. IC deposition in SLE and
RA is known to activate TLRs leading to increased IFNs,
and it has been hypothesized that autoantibody/ICs could
be important in the pathogenesis of SS [11, 24]. A sum-
mary of data suggesting a potential role for autoantibodies
and ICs in the pathogenesis of SS are listed in Table 2.
Viral infections, which strongly activate ICs and drive
IFN responses via TLRs, have long been implicated as a
trigger for autoimmune diseases like SLE, RA, and SS
[11, 23–25]. But so far, no associations have been found
between viral candidates like Epstein-Barr virus, hepatitis
C virus or retroviruses, and SS patients [11]. The long time
frame between initiation of disease and clinical diagnosis
makes it difficult to determine trigger events like viralinfection, which may have resolved months or years previ-
ously. Viral infections that were cleared months or years
earlier are not likely to account for the IFN signature in SS
because the immune response returns to normal after viral
clearance, and persistent viruses frequently “persist” be-
cause they do not induce strong IFN responses. However,
recent or reactivated viral infections would promote IFNs.
Sex differences in the immune response
An unresolved question is why most autoimmune dis-
eases occur more frequently in women than men. It is
well known that women respond to infection, vaccin-
ation, and trauma with increased antibody production
[33, 34]. Although increased antibody levels protect
women from infections, they also appear to increase the
risk of developing ADs. Estrogen activates B cells resulting
in increased levels of antibodies and autoantibodies, while
androgens decrease B cell maturation, reduce B cell syn-
thesis of antibody, and suppress autoantibody production
in humans [35–37]. Microarray and other molecular tools
have revealed in recent years how the immune response
under normal and pathologic conditions is extensively reg-
ulated by sex hormones. Sex steroid hormone receptors
such as the estrogen receptor (ER)-α, ER-β, androgen
receptor, and aromatase, the enzyme that converts an-
drogens to estrogens, are expressed on the cell surface
and/or intracellularly in immune cells. Likewise, cytokine
receptors like interleukin (IL)-1 receptor (IL-1R) are found
on classic hormone-producing tissues, indicating immune
regulation of sex hormones [38].
In cell culture studies and animal models, estrogen has
been shown to induce differentiation of DCs, stimulate T
cell proliferation, and increase T helper (Th)2 responses,
regulatory T cells (Treg), IL-4-driven alternatively activated
M2 macrophages, and the regulatory cytokines IL-4, IL-10,
and transforming growth factor (TGF)β [7, 35, 39–42].
Estrogen has also been shown to inhibit innate TLR re-
sponses and NF-κB thereby reducing IFNγ production
from immune cells [37, 40, 43, 44]. Intriguingly, autoanti-
bodies against ERα have been found to interfere with T cell
homeostasis and to be significantly associated with disease
activity in SLE patients [45]. That the immune response
would generate autoantibodies directed to ERα suggests
that estrogen is contributing to the disease process in
rheumatic ADs.
Far less research has been conducted on the effect of an-
drogens on immune cell function, but in general, andro-
gens drive IFNγ-associated Th1 responses [46, 47]. One
complication in understanding the role of sex hormones
on immune cells is that most studies do not interpret data
in the context of sex. For example, the sex of cells used in
culture experiments is seldom reported [48]. Additionally,
effects measured by testosterone may be due to testost-
erone or estrogen because of aromatase conversion. In
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gen driving Th2 responses, Dube et al. found in a retro-
spective cohort study of 15,357 adults that more men than
women were hospitalized for autoimmune diseases associ-
ated with Th1-type pathology, while more women than
men had autoimmune diseases associated with a Th2-type
response [49]. In particular, Th2-associated rheumatic auto-
immune diseases occurred more frequently in women than
men (adjusted hazards ratio 2.5, 95 % confidence intervals
1.6–3.9) [49]. Because Th1 (IFNγ) and Th2 (IL-4) responses
cross-regulate each other transcriptionally, the effect of
estrogen or testosterone in skewing Th responses may be
exaggerated. Thus, estrogen’s central role in driving a Th2-
type skewed immune response that activates B cells and el-
evates autoantibody and IC levels could be a contributing
factor in the increased risk for SS in women after triggers
like infection.
Risk factors
Pregnancy To date, there have been just two retrospe-
ctive case-control studies specifically investigating risk
factors for developing SS; the first study aimed to
identify perinatal influences associated with develop-
ing SS as an adult, and the second focuses on familial,
menstrual, and pregnancy history as factors contributing
to increased risk [50, 51]. By means of a 32 case (28
women to 4 men) and 159 control (139 women to 20
men) case-control study, Mostafavi et al. noted signifi-
cantly increased odds ratios (OR) for low maternal age
(26.1 vs. 28.3 years of age, p = 0.04) and high infant
birth weight (OR = 3.8, 95 % confidence intervals (CI):
1.3–11.7) as well as associations of SS with being the
first-born child (OR = 2.7, 95 % CI: 1.1–6.8), maternal
diseases during pregnancy (OR = 3.9, 95 % CI: 0.9-16.9),
and paternal socioeconomic status as a manual worker
(OR = 3.9, 95 % CI: 1.1-13.4) [50]. How perinatal
“stressors” (i.e., infections, first child, low income) influ-
ence the immune response is not yet clear, but a good
candidate includes epigenetic regulators like microRNAs
[52]. Although this study included men and women, the
data were not analyzed by sex.
In the second case-control study, Priori et al. evaluated
140 female SS patients (39 or 27.9 % were sSS) and 109
female controls [51]. Of the evaluated characteristics (con-
sanguinity, smoking habits, history of blood transfusions,
obstetric history, and family history of AD), a significant
association was observed with positive first-degree relative
history of AD (OR = 7.4, 95 % CI: 2.8–20.1) and in women
with one or more pregnancies (OR = 2.2, 95 % CI: 1.1–4.2)
or births (OR = 2.5, 95 % CI: 1.3–4.7) [51]. However, no
association was found between the age at menarche or
menopause and the risk of developing SS. More mothers,
sisters, and daughters had ADs compared to male first-
degree relatives, but this is not surprising because the ADsof first-degree relatives were ADs that occur predom-
inantly in women [8, 51]. Interestingly, pregnancy and
the presence of other ADs in patients (i.e., associated
SS) appeared to act synergistically to increase the risk
of developing SS. Patients with multiple ADs are likely
to have more distinct types of autoantibodies, which predict
risk for developing an AD [53]. It has been found that if
three autoantibodies are present compared to just one type
of autoantibody, an individual has a 60–80 % increased risk
of developing an AD [54]. It should be noted however that
SS patients can have successful pregnancies [55].
Additionally, during pregnancy, prolactin and estrogen
levels rise. Several clinical and animal studies have found
an association between elevated prolactin levels and SS
[56–59]. Not only does estrogen increase prolactin levels
but also estrogen and prolactin work together to increase
autoantibody levels and Ro/SSA and La/SSB autoanti-
bodies in particular [56, 60, 61]. However, IL-1β and IL-6
also increase prolactin levels, and so, it is not yet clear
whether elevated prolactin drives disease pathogenesis
or occurs as a result of pathology [61]. Regardless, once
prolactin is elevated, it is able to directly alter immune
function via prolactin receptors expressed on immune
cells like mast cells, macrophages, and T and B cells result-
ing in elevated autoantibodies [61]. Thus, pregnancy and
the presence of other ADs increase the risk for developing
SS. Two peaks for the appearance of SS have been reported,
one during child-bearing years around age 30 and far more
frequently shortly after menopause around age 55 [62].
Thus, prolactin may work together with high estrogen
levels to increase the risk for SS in premenopausal women.
Menopause Female predominance and disease onset fol-
lowing a major stressful event and/or following menopause
in SS patients suggest that the endocrine system and sex
hormones are involved in the pathogenesis of disease [63].
Menopause is defined as the final menstrual period without
another menstrual period for 12 months and occurs in
Western cultures at 49–52 years of age [64]. Large de-
creases in estrogen (i.e., estradiol) occur in the last 6 months
before menopause and thereafter, while testosterone grad-
ually decreases with age in both sexes. Understanding how
the menopausal transition affects inflammation is compli-
cated by changes in the immune response that occur with
aging. Autoantibodies continually increase with age in
women [65–67]. Importantly, lower doses of estrogen
present after menopause are still able to promote B cell
proliferation and autoantibody production following meno-
pause in women (Fig. 1). However, lower estrogen levels
may reduce the protective, anti-inflammatory effects of es-
trogen (i.e., estrogen increases Treg and regulatory macr-
ophages and inhibits proinflammatory NFκB) that were
present prior to menopause and allow increased activation
of TLR on innate immune cells resulting in elevated
Fig. 1 Possible role of estrogen in promoting Sjögren’s syndrome. In the context of genetic, epigenetic, and environmental influences like
infections and chemicals, the rapid decline in estrogen (E2) levels prior to menopause leads to reduced glandular cell health. Death of glandular cells
via apoptosis/necrosis provides self-antigens like nuclear antigens for presentation to the immune system to promote autoimmune disease. At the
same time, the protective effects of higher estrogen levels on inflammation disappear allowing increased activation of innate immune pathways like
toll-like receptor 4 (TLR4) and NFκB. In contrast, low levels of estrogen continue to increase the level and different types of autoantibodies with age
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[7] (Fig. 1).
That most women develop SS after menopause (age 55
or older) suggests that estrogen in general protects against
the development of SS [62, 68]. Alternatively, it may just
take more “time” to produce multiple autoantibodies
(Fig. 1). Evidence to support a protective role for estro-
gen in SS can be found in a recent study in mice where
ovariectomy of adult females (modeling menopause) in
a SS model significantly increased inflammation in the
lacrimal (tear) gland [69]. Estrogen replacement of ovariec-
tomized mice in these studies reversed the effect by redu-
cing T and B cell infiltration, suggesting that estrogen
reduces tear gland inflammation during SS. Note that re-
cruitment of B cells to tissues involves different immune
signaling pathways than activating B cells to produce anti-
body/autoantibodies, so that estrogen would be expected
to decrease inflammation but increase antibodies from B
cells at the same time. Ovariectomy of wild type female
mice has also been reported to cause SS-like disease with
apoptosis of salivary gland epithelial cells, indicating that
estrogen is needed for salivary gland cell survival [70]. Note
that apoptosis provides an important source of self-antigen
leading to the generation of self-reactive T and B cells and
autoantibodies [18, 71]. Thus, reduced levels of estrogen
with menopause could decrease the protective effect of es-
trogen by increasing inflammation and by reducing its pro-
liferative effects on glandular cells leading to increased
apoptosis (Fig. 1). In support of this idea, low salivary
estrogen levels have been found to correlate with a feel-
ing of dry mouth in healthy menopausal women [72]
and low circulating estrogen levels with ocular dryness
in SS patients [73]. Salivary gland epithelial cells ex-
press ERα and ERβ, and these cells from SS patients
have been found to have reduced responsiveness toestrogen (i.e., 17β-estradiol) [74, 75], a factor that may
be linked to the menopausal transition. Additionally,
aromatase deficient mice, which should prevent the
conversion of androgens to estrogen resulting in lower es-
trogen, develop a SS-like disease with increased inflamma-
tion of exocrine glands [76].
However, the role of sex hormones in SS is not straight-
forward. Oral dryness in SS patients has also been linked to
low circulating androgen levels [73]. Recall that androgen
as well as estrogen levels drop in women during and after
menopause. Circulating dehydroepiandrosterone (DHEA),
an adrenal prophormone that can be metabolized to estro-
gen and testosterone, is around 50 % lower in SS patients
than age- and sex-matched controls [77]. Salivary glands
from SS patients have also been found to have reduced
levels of DHEA [78]. Similar to the protective role of
estrogen, DHEA is needed for renewal of acinar cells of
the labial salivary glands and apoptosis of salivary gland
cells can be reversed by treatment of mice or patients
with androgens [73, 79, 80]. Thus, both estrogen and
androgens are needed for normal exocrine gland func-
tion. The reduction in circulating sex hormone levels
leading to increased apoptosis of exocrine gland cells
combined with the ability of estrogen, even at low doses, to
promote autoantibody formation could increase the risk in
women of developing SS (Fig. 1). Thus, these data support
the idea that estrogen protects against SS prior to meno-
pause but contributes to increased pathology after meno-
pause by increasing inflammation, autoantibody levels, and
death of tear duct and salivary gland cells resulting in dry
eye and mouth.
Immunogenetics There are a number of genes linked to
increased risk for developing SS. As for other ADs, genetic
and epigenetic associations with SS center on alterations
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number of the IgG receptor FcγRIIIb gene FCGR3B,
which facilitates clearance of ICs, was associated with
risk for developing isolated SS in a cross-sectional study of
174 SS patients compared to 162 controls (OR 2.3, 95 % CI
1.3–3.9, p = 0.003) [83]. Although 90 % of the SS patients
were female, while only 53 % of the controls were female;
no relationship was observed between FCGR3B copy num-
ber and sex [83]. But in order to draw conclusions about
sex differences in polymorphisms in this gene, a simi-
lar percentage of female patients and controls should
be examined.
Polymorphisms in IRF5 and STAT4 genes have been
associated with increased risk of isolated SS as well as
other ADs including SLE, Hashimoto’s thyroiditis, pri-
mary biliary cirrhosis, Graves’ disease, scleroderma, and
RA [11, 25–27, 84–86]. These genes promote Th1-type
immune responses by increasing type I (IFNα/β) and type
II (IFNγ) IFNs. Type I mRNA (i.e., IFNα) is upregulated in
the salivary glands and peripheral blood cells of SS patients
[84, 87, 88], but circulating IFNs were not found to correl-
ate with mRNA levels [84]. However, IL-12, a cytokine that
activates STAT4 leading to Th1 responses, has been found
to be elevated in the circulation of SS patients compared to
controls [89]. Although it has become clear more recently
that sex hormones influence Th1 vs. Th2 development,
these studies did not examine whether sex differences
exist in IRF5 or STAT4 polymorphisms in SS patients
and in some cases did not list the sex of the patients or
controls in the study [26, 27, 84].
MicroRNAs (miRNAs) are small non-coding RNAs that
post-transcriptionally regulate gene expression. Expression
of miR-146a has been found to be increased in peripheral
blood cells and salivary glands of mice and SS patients
compared to controls [90, 91]. miR-146a is upregulated in
macrophages following activation of TLR4 by lipopolysac-
charide and is thought to inhibit products of TLR4 sign-
aling like IL-1β and IL-18 [92]. However, IL-1β and IL-18
are elevated in the circulation and salivary glands of SS
patients and mice compared to controls [93, 94]. Add-
itionally, polymorphisms in IL-1β and IL-1R antagonist
(IL-1RA) increase susceptibility to SS [95, 96]. Although
IL-1β and IL-18 (originally named IFNγ-inducing factor)
are associated with proinflammatory responses and IL-18
increases Th1 responses, TLR4-induced IL-1β and IL-18
are also produced from alternatively activated, Th2-
associated M2 macrophages and mast cells [6, 8]. Thus,
upregulation of miR-146a in SS patients may be an at-
tempt to regulate the expression of IL-1β and IL-18. Al-
though to our knowledge, no one has studied whether sex
differences in miR-146a exist, as mentioned earlier, estro-
gen is known to inhibit TLR4 signaling. Thus, lower estro-
gen during and following menopause would be expected
to allow elevation of this pathway in the context of TLR4triggers like infection. Studies on the role of sex hor-
mones in this pathway in SS patients or animal models
are warranted.
Lastly, regulatory T cells (Treg) that express Foxp3 are
known to be under epigenetic control. Treg, which are
able to downregulate Th1-, Th2-, and Th17-type immune
responses, are increased in frequency in salivary glands and
the peripheral blood of SS patients compared to age and
sex-matched controls [97, 98]. Foxp3+ Treg levels were
found to positively correlate with the severity of disease in
SS patients including infiltrating monocyte/macrophages,
DCs, and serum complement C4 levels [97]. This may seem
somewhat surprising since elevated Treg should inhibit in-
flammation. Although Foxp3+ Treg may be attempting to
regulate the immune response in SS patients [98], their
numbers can also be increased by estrogen, Th2-type
immune responses, and TLR4 signaling [7, 44]. What is
generally missing from the study of genes that increase
the risk for SS is an assessment of whether sex differ-
ences exist.
Sex differences in serological markers
A component of the classification criteria for SS is based
on the presence of particular autoantibodies in the sera
(Table 1). Sjögren’s syndrome is commonly associated
with serological changes including hypergammaglobuli-
nemia and the presence of paraproteins, monoclonal im-
munoglobulin light chains that are produced in excess.
In addition, a diverse autoantibody profile of RF, ANA, Ro/
SSA, and/or La/SSB is observed [99]. There are a number
of studies that have considered whether sex differences
exist in the presence of autoantibodies between men
and women with SS (Table 3) [100–109]. Six of these
studies, totaling 1570 individuals with SS, found auto-
antibodies were increased in women compared to men
(Table 3). In contrast, 3 studies of a total of 950 SS pa-
tients found no sex difference in autoantibodies, and one
study of 549 patients found increased autoantibodies in
men (Table 3). The largest single study, which compared
938 women to 73 men with pSS, found that more women
were positive for ANA than men [109]. Recall that Ro/
SSA and La/SSB are types of ANA autoantibodies. One of
the obstacles in drawing conclusions from studies with
fewer individuals is that it may be difficult to obtain sig-
nificant differences between men and women because of
the small number of men in the study. Additionally, men
who are recruited to studies may have unusually high
autoantibody levels because the presence of autoanti-
bodies is part of the classification criteria for SS, thereby
reducing the potential for sex differences in autoantibodies
to be present.
In summary, autoantibodies were found to be elevated
in women with isolated SS compared to men in a greater
number of studies. In general, women were more frequently
Table 3 Sex differences in serology and extraglandular manifestations during Sjögren’s syndrome
Study (reference) site Classification criteria n (F/M) Serologic differences F > M Extraglandular manifestations F > M
1986 Molina [100] USA N/A 105 (69/36) RF, Ro/SSA, La/SSB No differences
1995 Anaya [102] USA European [103] 39 (26/13) No differences No differences
1997 Drosos [103] Greece European [103] 42 (30/12) ANA, Ro/SSA Raynaud’s phenomenon, polyarthritis
1999 Brennan [104] USA European [103] 42 (28/14) ANA, Ro/SSA Fatigue
1999 Saito [113] Japan American-European [13] 129 (117/12) Not performed Inflammation, sialectasis
2000 Cervera [101] Spain European [103] 223 (204/19) RF, ANA Raynaud’s phenomenon, cutaneous
vasculitis, polyarthritis
2004 Diaz-Lopez [105] Spain European [103] 549 (521/28) M > F: RF, ANA, IgA Fibromyalgia, thyroiditis
2007 Goeb [106] France American-European [13] 148 (137/11) ANA, Ro/SSA, La/SSB Raynaud’s phenomenon
2008 Horvath [107] Hungary American-European [13] 492 (432/60) No differences Raynaud’s phenomenon, thyroiditis
2008 Gondran [108] France American-European [13] 419 (377/42) No differences Lymphopenia, leucopenia
2008 Ramos-Casals [109] Spain European [103] 1,010 (938/73) ANA Raynaud’s phenomenon, thyroiditis
Table 4 Summary of sex hormone effects on Sjögren’s
syndrome (SS)
• Estrogen activates B cells increasing autoantibodies and ICs,
testosterone inhibits B cells decreasing autoantibodies and ICs
• Some studies report more autoantibodies in women with SS
compared to men
• Exocrine gland inflammation is elevated in women with SS
compared to men
• SS in women is associated with other ADs that occur predominantly
in women like RA, thyroiditis, and Raynaud’s phenomenon
• Lymphoma occurs more frequently in men with SS
• Most cases of SS occur in women following menopause indicating
that, in general, estrogen protects against SS prior to menopause
• Prolactin released during pregnancy may increase premenopausal
SS cases
• Prolactin acts synergistically with estrogen to increase Ro/SSA and
La/SSB
• Low estrogen levels after menopause continue to elevate
autoantibodies
• Estrogen protects against SS-like disease in animal models
• The androgen DHEA protects against SS in patients
• Estrogen and DHEA is decreased following menopause when most
SS cases occur
• Low estrogen levels correlate with dry mouth and ocular dryness
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La/SSB (two studies) (Table 3) [100, 101, 103, 104, 106, 107,
109]. However, two large studies did not confirm this assess-
ment [105, 108]. All studies but two reported no sex differ-
ence for RF. There are several possible explanations for the
inconsistencies that occurred between studies. Some studies
used the European classification criteria [110], while others
used the American-European criteria [15]. Most studies had
a female to male ratio of 9:1 but Diaz-Lopez et al. studied a
population with a ratio of 18:1 [105] and the ratio was 13:1
for the Ramos-Casals et al. study [109], which may have al-
tered the outcome. Most studies examined patients around
55 years of age, but a few studies examined a more elderly
(i.e., 65 years) or younger (i.e., 45 years) population. It is also
likely that differences exist in the ability of different ELISAs
to detect autoantibodies, which would alter detection rates.
Additionally, many different ethnic groups are represented
in these studies, which may differ in susceptibility to SS. In
spite of these differences, a number of studies have found
that SS-associated autoantibodies occur more frequently in
women with isolated SS. However, more research is needed
in this area to determine whether sex differences in auto-
antibody levels exist and if so, how this difference impacts
the pathogenesis and diagnosis of disease.
Sex differences in clinical manifestations
Isolated SS in men is rare. Though no study has been de-
signed to measure the prevalence of isolated SS in men,
the relatively low number of males in the published litera-
ture to date supports this statement (Table 3) [100, 101,
103, 104, 106, 107, 109, 111]. Paradoxically, in spite of the
overwhelming prevalence of the disorder in women, the
first patient described to have primary Sjögren’s syndrome
by Mikulicz in 1888 was a 42-year-old male farmer with
bilateral parotid and lacrimal gland enlargement [112].
There are a number of clinical SS studies focused on dif-
ferences in extraglandular disease expression between thesexes (Table 3) [100–109, 113, 114]. Two studies did not
observe sex differences in extraglandular manifestations
[100, 102]. However, the patients in the Anaya et al. study
(the age of patients in the Molina et al. study was not de-
scribed) were young (<40 years of age), which may account
for the observation since tissue damage would be expected
to take time to develop. In one of the largest cohorts pub-
lished to date, where 73 of 1010 patients were male (7 %), a
lower frequency of Raynaud’s phenomenon and thy-
roiditis was found in men compared to women (Table 4)
[109]. This observation was confirmed in several other
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show a higher frequency of depression [108], fibromyalgia/
fatigue [104, 105], and thyroiditis [105, 109]—condi-
tions known to occur more frequently in women than
men [8, 115–117].
Raynaud’s phenomenon occurs most frequently with
connective tissue autoimmune diseases (96 %) like mixed
connective tissue disease (86 %), SLE (31 %), RA (22 %),
and SS (13 %) [117]. The main pathology of Raynaud’s
phenomenon is associated with dysregulation of autonomic
and small sensitive nerve fibers resulting in abnormal,
long-lasting vasoconstriction of peripheral small vessels
[116, 117]. ANA autoantibodies are found in patients with
Raynaud’s phenomenon and are believed to be involved in
the pathogenesis of disease [117]. Sex hormones are also
thought to play a role in the pathogenesis of disease, with
the incidence of Raynaud-like vasospastic reactions in-
creased during the pre-ovulatory period and with estro-
gen administration [118].
In contrast, a disease that is dominant in men over
women with isolated SS is lymphoma (Table 4). Anaya
et al. reported the prevalence of malignant lymphoma in
men with isolated SS to be 15.4 % [102], higher than the
4–9 % commonly reported [111, 119–121]. The observ-
ation of a higher risk of lymphoma in men has been re-
cently confirmed in a large group of patients with isolated
SS from Italy where cumulative demographic, clinical,
serologic, histological, and therapeutic data of 1115 (1067
women is to 48 men) isolated SS patients were retrospec-
tively evaluated. Fifty cases of non-Hodgkin’s lymphoma
were documented with an overall prevalence of 4.5 % and
male sex was established as an independent risk factor
[111]. An additional three studies demonstrated a slightly
higher but not significant prevalence of lymphoma in men
compared to women with isolated SS [106, 108, 122]. Ac-
cording to Gondran et al., lymphoma development occurs
earlier in males than females following SS diagnosis [108].
These reports correspond with the observation that isolated
SS mortality in men is three times that in women, at least
in Eastern populations where both the onset and diagnosis
of SS occurs later for men [104, 105, 107, 108, 123]. Overall,
the strength of the association between lymphoma develo-
pment and SS seems to be stronger in men than women,
even if the underlying autoimmune disease prevalence
is, as expected, far higher in women than men [124, 125].
In general, lymphoma has been reported to occur more
frequently in men than women [126]. Animal models have
shown that T cell lymphomas are larger in male compared
to female mice [127]. And finally, women taking oral
contraceptives have been found to have a reduced risk
of developing non-Hodgkin’s lymphoma by up to 50 %
[128, 129]. These data suggest that sex hormone regulation
of immunopathology determines sex differences in extra-
glandular presentations during SS.Sex differences in SS immunopathology: evidence from animal
models
Concerning the immunological expression of disease, most
authors agree that whether according to histologic, sia-
lographic, and/or immunologic assessment, SS is slightly
less severe in men than in women (Tables 3 and 4)
[100–103, 109, 113, 114]. A small study by Saito et al.
found a lower prevalence of SS-related clinicopatho-
logic and sialographic changes in men with SS than in
women [113]. The mean stimulated parotid flow rate
was higher in men than women while the prevalence
of SS-related sialographic findings, such as globular
and punctate sialectasis, and grade 4 cases based on la-
bial salivary gland biopsy were lower in men compared to
women with SS [113], suggesting men have less inflamm-
ation than women. Additionally, ocular objective tests seem
to be less frequently altered in men [109]. Lastly, in a study
comparing 377 women to 42 men, Gondran et al. found
greater frequency of lymphopenia and leucopenia in
women, but greater thrombopenia in men [108].
Consistent with clinical observations, animal models
of SS have found that female mice have greater lacrimal
and salivary gland inflammation than males in animal
models of SS with a more predominant Th2 and Th17
response and more B cells [130–134]. An epidemiologic
study found that hormone replacement therapy in post-
menopausal women increased the risk of dry eye syn-
drome [135], suggesting that high doses of estrogen could
increase inflammation. In contrast, ovariectomy of adult
female mice in a SS model significantly increased inflam-
mation in the lacrimal gland [69], indicating estrogen
reduces inflammation. In support of this, estrogen re-
placement of ovariectomized mice reduced T and B cell
infiltrations, indicating that estrogen reduces lacrimal
gland inflammation during SS.
The clinical and mouse data appear to be contradi-
ctory, but there is a possible explanation. High doses of
estrogen are known to have an opposite effect on inflam-
mation than low doses [6, 8], and so, hormone replacement
therapy may not exactly mimic pre-menopause conditions.
Estrogen is known to decrease inflammation by increasing
Treg, Th2 responses, and regulatory cytokines like IL-10
and TGFβ [7, 35, 39–42]. In contrast, high doses of estro-
gen can increase inflammation, like during pregnancy and
with hormone replacement therapy. Estrogen, but not tes-
tosterone, is necessary for increased antibody and autoanti-
body levels and thereby participates in the development of
ICs. This is true even for low doses of estrogen. IC depo-
sition is a strong activator of complement, innate immune
mechanisms like TLR4 and increases inflammation [6].
Thus, an explanation for the data is that estrogen in females
is increasing inflammation via autoantibody/IC-mediated
mechanisms. In other words, estrogen can increase inflam-
mation through the antibody arm of the immune response
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reduced estrogen with menopause decreases the regulatory,
protective effects of estrogen on inflammation but should
not reduce its ability to promote inflammation via autoanti-
bodies and ICs.
Testosterone may also increase inflammation during SS.
Post-menopausal women with isolated SS were found to
have higher levels of testosterone that positively correlated
with disease activity [136]. There is evidence to suggest
that testosterone increases classic inflammation but not
autoantibody/IC levels. Although far less research has
been conducted on the effect of androgens on immune cell
function, in general, androgens drive cell-mediated IFNγ-
associated Th1 responses and inhibit antibody production
[46, 47]. For this reason, men are less likely to meet the
classification criteria for diagnosis of SS. Importantly, de-
creases in estrogen levels following menopause could
decrease the protective effect of estrogen including its
organ-promoting proliferative effects on glandular cells
leading to increased apoptosis and disease (Fig. 1) [80].
That most cases of isolated SS occur shortly after meno-
pause at around age 55–60 suggests that the sudden drop
in estrogen and/or a shift in the estrogen to androgen ratio
contribute to disease pathology [137]. In support of this
idea, low salivary estrogen levels have been found to cor-
relate with a feeling of dry mouth in healthy menopausal
women [72].
Another theory proposed to explain the sex difference
in SS suggests that lower estrogen levels in females after
menopause reduce salivary gland-specific TGFβ produc-
tion allowing increased inflammation. Microarray con-
ducted on normal salivary glands from men and women
without SS found that women had lower expression of
TGFβ compared to men [138]. Wild type female mice
with the TGFβ receptor inactivated developed salivary
gland inflammation and an increased Th1-type immune re-
sponse [139], suggesting that this mechanism could influ-
ence inflammation.
Not only is estrogen lower following menopause but
also the adrenal pro-hormone DHEA, which is reduced
by around 50 % in SS patients compared to healthy age-
and sex-matched controls [77]. DHEA is important for
the repair and renewal of acinar cells of the labial saliv-
ary glands and impaired levels of DHEA can lead to
apoptosis of these cells [80]. DHEA has been used as a
therapy in SS patients, where administration reduced symp-
toms of dry mouth [73]. Reduction in DHEA with meno-
pause resulting in apoptosis could lead to upregulation of
TLR and activation of the inflammasome (e.g., TLR4,
caspase-1, IL-1β, IL-18, IFNs) leading to salivary gland
inflammation. The inflammasome does appear to be ac-
tivated during SS in humans and animal models [94, 140].
Genetic polymorphisms in IL-1β or IL-1 receptor antagon-
ist (an inhibitor of IL-1R signaling) are believed to affect SS[95, 96], and IL-1 is one of the prominent cytokines de-
tected in salivary glands of SS patients [141]. Additionally,
IL-18, a component of the inflammasome, was found to be
present in macrophages within inflammatory foci of the sal-
ivary gland of SS patients and circulating IL-18 levels were
elevated in SS patients compared to controls [93]. Interest-
ingly, serum IL-18 levels were strongly correlated with Ro/
SSA and La/SSB autoantibodies. Although SS has tradition-
ally been considered a Th1-driven immune response, this
could be due to IL-18 rather than the classical IL-12-
induced Th1 pathway because IL-18 strongly drives Th1
differentiation resulting in elevated levels of IFNs. Activa-
tion of the inflammasome results in a mixed Th1/Th2-
type immune response [6–8]. Th2 responses are required
for increased autoantibody levels. A mixed Th cytokine
profile has been demonstrated in the salivary gland of pa-
tients where IL-4, IL-13, IL-17A, and IFNγ levels were
found to be significantly higher in SS patients compared
to controls [142, 143]. Additional support for the idea that
Th2 responses could be important for SS comes from the
finding that SS patients had significantly higher levels of
circulating IL-13 compared to controls [144].
Microchimerism
Although this review has focused on sex differences in
the immune response during Sjögren’s syndrome, the poss-
ibility that the increased incidence of disease in women
could be due to microchimerism should also be mentioned.
Microchimerism is the presence of non-host stem cells or
their progeny in an individual at a low level. This occurs
during pregnancy, in twins and with blood transfusions or
transplantation [145–147]. Microchimerism can occur as
early as 6 weeks into pregnancy. A wide variety of fetal cells
have been detected in the maternal circulation including
mesenchymal stem cells, hematopoietic progenitor cells,
nucleated erythroblasts, CD34+ stem cells, and im-
mune cells like monocytes, natural killer cells, T cells,
and B cells [147]. This finding led to the hypothesis
that microchimerism in women following pregnancy with
sons may be involved in the pathogenesis of autoimmune
diseases. This concept was also thought to account for sex
differences in disease because mothers with non-host cells
from their sons may be predisposed to develop auto-
immune disease if they have the right genetic background
(i.e., HLA susceptibility for example) [145]. The primary
mechanism is thought to involve a graft-vs.-host (GVH)
inflammatory response, which is the primary inflamma-
tory concern following blood transfusions and transplant-
ation including stem cell transplantation.
Initial evidence that microchimerism may be involved
in SS comes from a number of reports of patients develop-
ing a SS-type disease following blood transfusion, stem cell
transplantation, or during GVH disease [148–150]. Several
studies have examined SS patients to determine whether
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SS to healthy control women who had given birth to at
least one son and found evidence of male cells in the saliv-
ary gland biopsy of 11/20 patients compared to 1/8 controls
[151]. A similar study by Kuroki et al. found that 10/28
women with SS and previous male pregnancies had evi-
dence of microchimerism in their salivary gland while
0/10 control women did not [152]. All studies so far agree
that if microchimerism exists, it is found in the salivary
gland and not in peripheral blood cells. However, several
other studies found no evidence of microchimerism in SS
women who had given birth to at least one boy [153–155].
Although this is an interesting theory, there are a num-
ber of issues that need to be resolved. One is that GVH
disease occurs suddenly and aggressively when foreign cells
are introduced to the host, but SS peaks after menopause
around 20 to 30 years after giving birth to a boy. So if
GVH disease is a pathomechanism, why does it take so
long to develop disease? Secondly, microchimerism is
bi-directional meaning that boys also obtain cells from
their mothers [145–147]; so why wouldn’t men also be
predisposed to autoimmune/GVH disease by this mechan-
ism? Thirdly, it is not uncommon for healthy individuals to
develop microchimerism [145], so perhaps the associations
found by Endo et al. and Kuoki et al. would diminish with
an increased sample size. Additionally, there is some evi-
dence that microchimerism may be immunoregulatory and
reduce the risk of graft rejection if a microchimerism is
present [147, 156, 157]. And finally, microchimerism is
known to persist in immunodeficient individuals [146], so
the possibility exists that microchimeric cells simply persist
in patients with SS because their immune response is dys-
regulated. Thus, little clear evidence exists for the role of
microchimerism in the pathogenesis of SS, and more re-
search is needed to determine whether this mechanism
could skew the prevalence of disease toward women.
Conclusions
Although Sjögren’s syndrome can occur in women dur-
ing child-bearing years, most cases of SS occur soon
after menopause around age 55–60. Clinical and animal
model evidence indicates that estrogen and androgens
like DHEA promote gland cell survival and protect against
exocrine gland inflammation; and these hormone levels
decline at menopause. Even though estrogen levels drop
significantly prior to menopause and androgens gradually
decrease, low levels of estrogen continue to drive autoanti-
body diversity. Other female-dominate rheumatic ADs like
SLE and RA increase the risk of developing SS and gener-
ate similar autoantibody profiles. Extraglandular manife-
stations of SS follow typical sex difference predominance
with thyroiditis, Raynaud’s phenomenon, depression, and
fibromyalgia occurring more frequently in women than
men, while lymphoma occurs more frequently in men.Overall, estrogen may increase the incidence of SS in
women by increasing autoantibody production, even
following menopause, leading to IC deposition, tissue
damage, TLR/ inflammasome activation, elevated IFNs,
and exocrine gland dysfunction. Importantly, sex hormones
most likely contribute to SS pathology in the context of
genetic predisposition and environmental triggers like
infections.
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